Lupin plans to launch around 25 products in US in FY17

16 Aug 2016 Evaluate

Drug major Lupin is planning to launch around 25 products in the US market in FY17. Apart from the Gavis portfolio, Fortamet and Glumetza, the company is expecting to launch products like Minastrin and Epzicom. The Mumbai-based firm is planning to go ahead with launches on the dermatology front this year.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2103.30 -8.70 (-0.41%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×